Terazawa T, Matsuyama J, Goto M, et al. - Given non-satisfactory outcomes have been reported with D2 gastrectomy followed by adjuvant S-1 in patients (pts) with stage III gastric cancer (GC), researchers investigated whether perioperative capecitabine and oxaliplatin (CapeOx) affords an effective option for pts with GC. The presence of clinical T3(SS)/T4a(SE) N1-3 M0 GC confirmed by the Japanese Classification (JCGC; 3rd English Edition) was required for the inclusion of the cases. Participants were administered 3 cycles of neoadjuvant CapeOx (capecitabine, 2,000 mg/m² for 14 days; oxaliplatin, 130 mg/m² on day 1, every 3 weeks), followed by 5 cycles of adjuvant CapeOx following D2 gastrectomy. The pathological response rate as per the JCGC (≥ grade 1b) was the primary endpoint. Along with sufficient pathological response, good feasibility and favorable efficacy were reported for perioperative treatment with CapeOx, however, statistical significance at .058 did not reach the commonly accepted cutoff of .05.